All In MedTech

Device Trial Radar · NCT06165510

Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Aug 2, 2024

Primary completion

Nov 1, 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Barts & The London NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AtriCure, Inc.
First posted
Dec 11, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation (AF).

Conditions

  • Persistent Atrial Fibrillation
  • Atrial Fibrillation, Persistent
  • Atrium; Fibrillation
  • Atrial Arrhythmia

Interventions

  • Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.Device

    2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.

  • Standard Endocardial Catheter AblationProcedure

    Standard percutaneous endocardial catheter ablation of atrial fibrillation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstrate trial feasibility with regards to recruitment rateTime frame: 24 months
  2. A composite of major adverse events (MAE) and complications occurring within 30 days post procedure will be measured.Time frame: 30 days post procedure
  3. Success or failure at 12 months of persistent AF patients to be free of: Atrial arrhythmia (classed as documentation of atrial fibrillation, atrial flutter or atrial tachycardia lasting for more than 30 seconds)Time frame: Measured from the end of a 3 month blanking period to 12 months post procedure

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St Bartholomew's Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.